Agora Financial’s FDA Trader is designed to alert you to breakout moves in the medical markets, whether that be an announcement from the FDA or an overlooked drug trial that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market… to the outsized gains we see ahead for these specialized kinds of plays.
What kind of gains? In 2013 alone, the drug stock Celldex was up 408%. Insys shot up 411%… Lannett rose 526%… and BioTelemetry went up 416%. These gains are more than achievable. Our four-part portfolio consists of plays that could go up 50–100% within a three-week to three-month holding period, along with more buy-and-hold strategies that we expect will pay out up to 500% gains over the course of three–five years.
Biotechnology and medical technology are never going to go away. There will always be a demand to fix the things that go wrong with our bodies. Diabetes was not something that anybody really cared about 30 or 40 years ago. Today, about a third of the U.S. will have diabetes in the near future. So in other words, there will always be a need for medical technology and medical innovation. There’s no biotechnology fund will use this tried-and-true four-part trading system.